Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex (NASDAQ: GNPX) will present its diabetes gene delivery approaches at the virtual Future of Cell and Gene Therapy Symposium, November 17–18, 2026.
Pier-Anne Lachance, Senior Director of Quality Control & Product Development, will discuss parallel development of adeno-associated virus (AAV) and non-viral lipid-based delivery, including manufacturing and product development considerations. Both approaches remain in preclinical development. The AAV approach is designed to deliver Pdx1 and MafA genes to the pancreas to reprogram cells toward insulin-producing function. Genprex is evaluating lipid-based delivery for potential administration flexibility, including repeat dosing. The company intends the parallel evaluation to inform development decisions as it works toward studies needed before seeking permission for human trials.
Genprex (NASDAQ: GNPX) presented a REQORSA gene-therapy analysis linking increased TUSC2 expression to cellular repair and maintenance pathways in patients. The whole-blood analysis covered 11 lung cancer patients in two clinical trials, with samples taken before treatment and 5 and 24 hours after intravenous administration.
At 5 hours, immune-related activity dominated, consistent with a nonspecific reaction to the lipid nanoparticle delivery system. By 24 hours, that response partially subsided as genes involved in mitochondrial adaptation, cellular waste recycling and protein quality control increased. Immune surveillance pathways also rose, while protein-production and IGF/mTOR-associated growth pathways were suppressed. Mitochondrial energy-production genes dipped at 5 hours and recovered by 24 hours. Genprex said the findings may inform broader exploration of REQORSA; they describe gene-expression changes rather than demonstrated anti-aging benefits.
Genprex (GNPX) announced research identifying TROP2 expression as a potential marker of response to its REQORSA gene therapy in lung cancer. Low TROP2 expression was associated with resistance across preclinical models of non-small cell lung cancer; analysis of pretreatment patient tumor biopsies supported the association with treatment response.
Approximately 50% of 10 cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery. Experimentally changing TROP2 expression altered cancer cell death induced by TUSC2, suggesting a possible role in treatment sensitivity. Further research and prospective clinical evaluation are required to establish TROP2's ability to predict patient response. The research will be presented on November 18, 2026, at the EORTC-NCI-AACR Symposium in Barcelona.
Genprex (GNPX) will present research from its sponsored Meharry Medical College collaboration at the Gerontological Society of America meeting on November 4, 2026. The poster examines TUSC2, the gene used in its investigational REQORSA gene therapy, and its role in mitochondrial biology, cellular resilience and aging-related processes.
Chief Medical Officer Mark S. Berger will present the poster at the meeting in National Harbor, Maryland. The collaboration began in 2024. Genprex is working with Meharry to expand the research into REQORSA's role in aging-related biology. The company views the work as potentially informing applications beyond oncology, but additional research is needed to determine whether the findings could support future therapeutic development. The poster is expected online after presentation, subject to conference disclosure requirements.
Genprex (NASDAQ: GNPX) highlighted peer-reviewed mouse research linking loss of TUSC2, the gene used in investigational REQORSA, to brain-aging changes.
The Meharry Medical College study, published in Mechanisms of Ageing and Development, found that TUSC2 loss disrupted mitochondrial function, protein quality control and neuronal communication pathways in the hippocampus, a brain region involved in learning and memory. Effects were more pronounced in males; females showed adaptive cellular stress responses. Analysis of existing human datasets found that TUSC2 expression declined significantly with age in 11 of 13 examined brain regions, with additional reductions in Alzheimer's disease datasets. Mouse findings overlapped with molecular changes in human hippocampal aging data. The study did not evaluate REQORSA as a treatment for aging or neurodegenerative disease; its development remains focused on cancer.
Genprex (GNPX) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026.
President and CEO Ryan Confer will give an overview of Reqorsa® Gene Therapy, the company’s lead clinical oncology candidate, and its preclinical diabetes program, including development priorities. Chief Medical Officer Mark Berger, MD, and Senior Vice President of Intellectual Property and Licensing Thomas Gallagher will attend and participate in one-on-one investor meetings.
Reqorsa (quaratusugene ozeplasmid) uses the systemic, non-viral ONCOPREX® Delivery System to deliver the TUSC2 tumor suppressor gene and is being evaluated in the Acclaim-1 and Acclaim-3 trials for non-small cell and small cell lung cancer, which have FDA Fast Track designations and an Orphan Drug designation for small cell lung cancer.
Genprex (NASDAQ:GNPX) announced a development and manufacturing agreement with a leading U.S.-based clinical and commercial CDMO to scale up manufacturing of its AAV-based diabetes gene therapy program. The CDMO will produce cGMP-compliant drug product for Genprex’s IND-enabling preclinical studies and planned future clinical trials.
The roadmap includes process optimization using advanced AAV technologies, bioreactor scale-up, analytical qualification and potency assay development, and strict GMP compliance. Genprex’s candidate delivers Pdx1 and MafA genes to the pancreas, aiming to convert alpha cells into insulin-producing beta-like cells in T1D and rejuvenate exhausted beta cells in T2D, with supporting mouse and NHP preclinical data.
Genprex (NASDAQ: GNPX) announced a collaboration with Roche Diagnostics to validate biomarker assays for patient selection in non-small cell lung cancer (NSCLC) clinical trials. The work focuses on using TROP2 as a biomarker, informed by Genprex data linking high TROP2 and low PTEN H-scores to improved Progression Free Survival (PFS) in NSCLC patients.
According to Genprex, Roche Diagnostics, which received FDA Breakthrough Device Designation for an AI-driven TROP2 companion diagnostic, will perform assay validation using its established TROP2 antibody. Genprex plans to complete validation studies by approximately the end of 2026 and then seek to integrate TROP2-based patient selection into its NSCLC clinical program, depending on validation results. The collaboration is intended to support more precise enrollment in studies of Genprex’s lead product candidate, Reqorsa Gene Therapy, and advance biomarker-driven precision medicine in oncology.
Genprex (NASDAQ:GNPX) received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering Reqorsa gene therapy combined with PD-1 or PD-L1 antibodies to treat NSCLC and SCLC. The patent covers combinations used in the Acclaim-3 trial with Tecentriq and expands Genprex's global IP portfolio.
Genprex (NASDAQ:GNPX), a clinical-stage gene therapy company developing treatments for cancer and diabetes, will attend the BIO 2026 International Convention in San Diego from June 22-25, 2026.
Senior Vice President Thomas Gallagher will hold in-person one-on-one meetings about Genprex's gene therapy programs.